

Press Release



Notice Concerning Consolidation of Ha Tay Pharmaceutical Joint Stock Company as Consolidated Subsidiary

TOKYO, February 3, 2025 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/Representative Director: Sohta Yamaguchi, hereinafter “ASKA Pharmaceutical”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886) announced that the Company has decided to acquire additional shares of Ha Tay Pharmaceutical Joint Stock Company (hereinafter “Hataphar”), a Vietnamese pharmaceutical company, which is an equity method affiliate through market purchase, and to make it a consolidated subsidiary of ASKA Pharmaceutical, in accordance with the control criteria stipulated in the Accounting Standard for Consolidated Financial Statements, at the Board of Directors held on February 3, 2025.

1. Reason for Consolidation of Hataphar as a Consolidated Subsidiary

In its Medium-Term Management Plan 2025, ASKA Pharmaceutical Holdings Group aims to become a “Total Healthcare Company with a Strong Foundation as a Specialty Pharma Company.” In order to achieve the goals of the Medium-Term Management Plan, the Company has set four visions and seven strategies for the business activities, and one of the seven strategies is “Overseas Business Development.” The Company aims for further growth in the domestic pharmaceutical market, mainly in the field of obstetrics and gynecology, as well as establishing business in emerging countries, especially in Southeast Asia, where the market is growing rapidly due to population growth and economic development. Under such circumstances, ASKA Pharmaceutical and Hataphar have been cooperating as strategic partners. Since ASKA Pharmaceutical acquired 24.9% of Hataphar's shares in January 2021, it has continued to support Hataphar's new factory construction.

In order to further strengthen the relationship that has been cultivated so far and to move to the next step in all business activities, including manufacturing, sales, and development, the Company has decided to acquire additional shares of Hataphar through market purchase and make it a consolidated subsidiary of ASKA Pharmaceutical by classifying it as a subsidiary based on the control criteria stipulated in the Accounting Standard for Consolidated Financial Statements. Through the consolidation of Hataphar as a consolidated subsidiary of ASKA Pharmaceutical, the Company, including Hataphar, will realize further growth and increase its corporate value.

2. Outline of the Company to Become a Subsidiary

(1) Trade name	Ha Tay Pharmaceutical Joint Stock Company
(2) Location	No. 10A Quang Trung street, Ha Dong district, Hanoi, Vietnam
(3) Title and name of representative	Chairman of the Board of Directors, Mr. Le Van Lo
(4) Business	Manufacture, import and sale of ethical pharmaceuticals, over-the-counter drugs, health foods, etc.
(5) Capital	823,417,730,000 VND
(6) Establishment	1965

(7)	Major Shareholders and Shareholding Ratio	ASKA Pharmaceutical Co., Ltd. 39.94%		
(8)	Relationship between the Company and Hataphar	Capital relationship	Hataphar is an equity-method affiliate of the Company.	
		Personal relationship	The Group dispatches Board Members (two members of the Board of Directors) to Hataphar.	
		Business relationship	The Company guarantees Hataphar's borrowings from financial institutions.	
(9)	Consolidated financial results and consolidated financial position of Hataphar for the past three years			
	Fiscal Year	FY ended December 31, 2021	FY ended December 31, 2022	FY ended December 31, 2023
	Consolidated net assets	4,429 million yen	4,671 million yen	6,264 million yen
	Consolidated total assets	7,739 million yen	9,143 million yen	11,375 million yen
	Consolidated net assets per share	53.79 yen	56.73 yen	76.08 yen
	Consolidated net sales	9,931 million yen	11,338 million yen	12,337 million yen
	Consolidated operating profit	330 million yen	629 million yen	582 million yen
	Consolidated ordinary profit	481 million yen	733 million yen	636 million yen
	Profit attributable to owners of parent	348 million yen	561 million yen	480 million yen
	Earnings per share	4.23 yen	6.81 yen	5.83 yen
	Dividend per share	6.17 yen	6.17 yen	3.08 yen

* 1VND= 0.006171 JPY

3. Number of Shares to be Acquired, Acquisition Price, and Shareholdings Before and After the Acquisition

(1)	Number of shares held before the transfer	32,885,239 shares (Percentage of voting rights held: 39.9%)
(2)	Number of shares to be acquired	90,000 shares
(3)	Number of shares to be held after the transfer	32,975,239 shares (Percentage of voting rights held: 40.0%)

4. **Schedule**

(1) Date of resolution by the Board of Directors	February 3, 2025
(2) Implementation date of the Acquisition of Shares	Within February 2025 (scheduled)

5. **Outlook**

The impact of this transaction on the Company's consolidated financial results for the fiscal year ending March 31, 2025 is expected to be minimal. The Company's consolidated earnings forecast will be announced in the Financial Results for the fiscal year ending March 31, 2025.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp